Clinical Trials Browser

Phase 2 × Pancreatic Neoplasms × toripalimab × Clear all

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06080854 2023-10-12

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms